Peer-reviewed veterinary case report
Comparing single vs divided cyclophosphamide doses in dog lymphoma
By Atc Liao et al.·Published in Veterinární Medicína·2020·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of the cytotoxic effects of single and divided treatment of 4-hydroxycyclophosphamide at the same total dosage amount in canine lymphoma cell lines
- Species:
- dog
Plain-English summary
A study looked at how different ways of giving a chemotherapy drug, cyclophosphamide, affect dogs with lymphoma. The researchers tested a single large dose versus smaller doses given over several days. They found that while the single dose worked better for B-cell lymphoma, both methods had similar effects on T-cell lymphoma. Despite the potential for bladder irritation with the drug, the single maximum dose is still recommended for treating dogs with B-cell lymphoma.
People also search for: dog lymphoma treatment options · cyclophosphamide side effects in dogs · chemotherapy for B-cell lymphoma in dogs
Abstract
Cyclophosphamide is widely used in combination chemotherapy to treat dogs with lymphoma. The metabolite of cyclophosphamide, acrolein, can irritate the urinary bladder and cause sterile haemorrhagic cystitis. The divided administration of cyclophosphamide across multiple days may reduce the occurrence of the cystitis. However, the therapeutic effect of this modification has not been evaluated and compared to the traditional single maximum-tolerated dose. It is difficult to evaluate the cytotoxic effect by the single chemotherapeutic drug in dogs. In order to verify the effect of the single and divided treatment of cyclophosphamide in canine lymphoma, we used two canine lymphoma cell lines (CLBL-1, B-cell lymphoma and UL-1, T-cell lymphoma) to imitate the clinical conditions. The cell viability in the CLBL-1 and UL-1 cells treated by a single dosage of 4-hydroxycyclophosphamide after 48 h were 70.4% and 61.5%, respectively. The cell viability in the CLBL-1 and UL-1 cells treated by the divided dosage of 4-hydroxycyclophosphamide after 48 h were 109.4% and 50.8%. There were no significant differences between the two administration methods in the T-cell lymphoma cell line (P = 0.215). The single full dosage of 4-hydroxycyclophosphamide exhibited a significant cytotoxic effect rather than the divided dosage in B-cell lymphoma cell line (P = 0.007) did. The maximum-tolerated dose of cyclophosphamide is still recommended to be used in dogs with B-cell lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/377708cc678b4fddaac82b18ca4690b6a21620a7